FINANCIAL INFORMATION
Investor relations
Explore our latest press releases, financial reports, and materials from our annual meetings.
About Ortivus
Ortivus specializes in developing and commercializing MobiMed, e-health, and medical technology solutions aimed at enhancing healthcare safety and efficiency. Established in 1985, the company has evolved into a leading provider of mobile digital solutions for prehospital care on an international level. Ortivus’ innovations stem from profound expertise in cardiology and years of collaborative development with users and clients. Headquartered in Danderyd, Stockholm, the company also maintains a wholly-owned subsidiary in the United Kingdom since 1998.
Ortivus’ Class A and Class B shares are listed on the NASDAQ Stockholm Small Cap list.
Why invest?
The digitization of healthcare is becoming increasingly crucial to meet the future demands of the healthcare sector. Alongside the challenges posed by Covid-19, we are witnessing a surge in patient volumes coupled with limited financial resources. To ensure efficient and safe care delivery, we must embrace new working methods and technical innovations.
As part of this evolution, many ambulance services are transitioning to electronic patient records and adopting systems for real-time sharing of patient information throughout the prehospital care chain. Similarly, primary care is integrating solutions to remotely monitor and treat patients to a greater extent. Progress in the development of modern e-health solutions is underway and the segment is expected to accelerate in the years ahead.
Ortivus has in-house development and production of monitoring equipment and is well equipped to meet the requirements of modern, adaptable and reliable healthcare solutions. With Ortivus’ MobiMed, you can review a patients’ vital sign such as ECG, blood pressure and heart rate in real time and at a distance. MobiMed facilitates diagnosis through advanced decision support and the ability to consult an expert remotely via video call or chat. With MobiMed, workflows are optimized, enabling advanced care remotely with unparalleled communication and data-sharing capabilities. With its modularity, flexibility and advanced features, MobiMed is well adapted for the future of healthcare.
Ortivus is currently established in numerous countries and is strategically positioned to expand MobiMed into an even broader international market.
The Ortivus share
Ortivus shares have been listed on the NASDAQ Stockholm Small Cap-list since January 2, 1997.
| Stock Symbol | ISIN | Shares Outstanding | Votes/share | Total Number of Votes | |
|---|---|---|---|---|---|
| Class A | ORTI A | SE0000188930 | 1,662,682 | 10 | 16,626,820 |
| Class B | ORTI B | SE0000123085 | 42,644,786 | 1 | 42,644,786 |
The share capital is SEK 15,507,614. Share capital is divided between class A and class B shares. The number of shares outstanding is 44,307,468 of which class A amount to 1,662,682 and class B to 42,644,786. Every class A share carries 10 votes and every class B share carries one vote.
Ortivus A
Ortivus B
Ortivus’ investors
| Top 10 investors | A-Shares | B-Shares | Number of Shares | Number of Votes | Share of Capital | Share of Votes |
|---|---|---|---|---|---|---|
| Ponderus Invest AB | 80 525 | 11 161 350 | 11 241 875 | 11 161 350 | 25.4% | 20.2% |
| Papaxanthis Konstantin | 658 200 | 0 | 658 200 | 6 582 000 | 1,5% | 11,1% |
| Nordnet Pensionförsäkring AB | 16 609 | 3 863 492 | 3 880 101 | 3 863 492 | 8,8% | 6,8% |
| Försäkringsbolaget Avanza Pension | 31 574 | 3 367 848 | 3 399 422 | 3 367 848 | 7,7% | 6,2% |
| Pär-Ola Adolfsson | 2 030 237 | 2 030 237 | 2 030 237 | 4.6% | 3.4% | |
| Ing-Marie Fraim | 2 006 401 | 2 006 401 | 2 006 401 | 4.5% | 3.9% | |
| Seligson & CO Founder | 1 566 092 | 1 566 092 | 1 566 092 | 3.5% | 2.6% | |
| Nils-Arne Eriksson | 1 550 625 | 1 550 625 | 1 550 625 | 3.5% | 2.6% | |
| Raspart Förvaltning AB | 1 013 226 | 1 013 226 | 1 013 226 | 2.3% | 1.7% | |
| Anna Fuhr | 946 018 | 946 018 | 946 018 | 2.1% | 1.6% | |
| Other | 875 774 | 15 139 497 | 16 015 271 | 23 897 237 | 36.1% | 39,9% |
| Total | 1 662 682 | 42 644 786 | 44 307 468 | 57 984 526 | 100% | 100% |
Read our latest reports
Financial reports
Quarterly Reports
Yearly Reports
Our upcoming events
IR calender
| Interim report Q1 | 8 April 2024, 8:30 am |
| Annual General Meeting | 8 April 2024, 3:00-4:00 pm |
| Interim report Q2 | 23 aug 2024, 8:30 am |
| Interim report Q3 | 8 nov 2024, 8:30 am |
| Interim report Q4 | 14 feb 2025, 8:30 am |
Subscribe to financial information
